These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 26924051)
1. Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Krane V; Schmidt KR; Gutjahr-Lengsfeld LJ; Mann JF; März W; Swoboda F; Wanner C; Kidney Int; 2016 Jun; 89(6):1380-7. PubMed ID: 26924051 [TBL] [Abstract][Full Text] [Related]
2. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. März W; Genser B; Drechsler C; Krane V; Grammer TB; Ritz E; Stojakovic T; Scharnagl H; Winkler K; Holme I; Holdaas H; Wanner C; Clin J Am Soc Nephrol; 2011 Jun; 6(6):1316-25. PubMed ID: 21493741 [TBL] [Abstract][Full Text] [Related]
3. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E; N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009 [TBL] [Abstract][Full Text] [Related]
4. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Hoffmann MM; März W; Genser B; Drechsler C; Wanner C Atherosclerosis; 2011 Dec; 219(2):659-62. PubMed ID: 21871624 [TBL] [Abstract][Full Text] [Related]
5. Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Chan KE; Thadhani R; Lazarus JM; Hakim RM Clin J Am Soc Nephrol; 2010 May; 5(5):856-66. PubMed ID: 20338963 [TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL; Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798 [TBL] [Abstract][Full Text] [Related]
7. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model. Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H; Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944 [TBL] [Abstract][Full Text] [Related]
8. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Wanner C; Krane V; Ruf G; März W; Ritz E Kidney Int Suppl; 1999 Jul; 71():S222-6. PubMed ID: 10412782 [TBL] [Abstract][Full Text] [Related]
9. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH; Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833 [TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Wanner C; Krane V; März W; Olschewski M; Asmus HG; Krämer W; Kühn KW; Kütemeyer H; Mann JF; Ruf G; Ritz E; Kidney Blood Press Res; 2004; 27(4):259-66. PubMed ID: 15316128 [TBL] [Abstract][Full Text] [Related]
11. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. Billings FT; Hendricks PA; Schildcrout JS; Shi Y; Petracek MR; Byrne JG; Brown NJ JAMA; 2016 Mar; 315(9):877-88. PubMed ID: 26906014 [TBL] [Abstract][Full Text] [Related]
12. Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Krane V; Heinrich F; Meesmann M; Olschewski M; Lilienthal J; Angermann C; Störk S; Bauersachs J; Wanner C; Frantz S; Clin J Am Soc Nephrol; 2009 Feb; 4(2):394-400. PubMed ID: 19158371 [TBL] [Abstract][Full Text] [Related]
13. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study. Waheed S; Pollack S; Roth M; Reichek N; Guerci A; Cao JJ Atherosclerosis; 2016 Dec; 255():193-199. PubMed ID: 27693004 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Kollerits B; Drechsler C; Krane V; Lamina C; März W; Dieplinger H; Ritz E; Wanner C; Kronenberg F; Nephrol Dial Transplant; 2016 Nov; 31(11):1901-1908. PubMed ID: 26754832 [TBL] [Abstract][Full Text] [Related]
15. Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis. Kopecky C; Genser B; Drechsler C; Krane V; Kaltenecker CC; Hengstschläger M; März W; Wanner C; Säemann MD; Weichhart T Clin J Am Soc Nephrol; 2015 Feb; 10(2):224-31. PubMed ID: 25424990 [TBL] [Abstract][Full Text] [Related]